Browsed by
Tag: SHAREHOLDER

Here’s What Hikma Pharmaceuticals PLC’s (LON:HIK) Shareholder Ownership Structure Looks Like

Here’s What Hikma Pharmaceuticals PLC’s (LON:HIK) Shareholder Ownership Structure Looks Like

The Telegraph

Republican senators fear ‘bloodbath’ as Joe Biden extends lead

Republican senators are increasingly distancing themselves from the White House amid growing concerns Donald Trump could be facing a “bloodbath” defeat. Joe Biden’s lead over Mr Trump has grown to 9.6 per cent in an average of recent polls, just short of the 10 per cent figure sometimes used to define a “landslide”. Some Republican strategists and donors have begun suggesting a shift in resources to protect vulnerable Senate seats, arguing that keeping the Senate is the best way to put a check on a potential Biden presidency. Ted Cruz, the Texas senator who was runner-up to Mr Trump in the 2016 Republican presidential primary, said he was “worried” and the election was “highly volatile”. If Americans felt “optimistic” about the pandemic and economy on November 3, Mr Trump could still win by a “big margin”, he said. But he added: “I also think, if on Election Day people are angry and they’ve given up hope and they’re depressed, which is what [the Democrat leadership] want them to be, I think it could be a terrible election. “I think we could lose the White House and both houses of Congress, that it could be a bloodbath of Watergate proportions.” The Senate is held by Republicans with a 53-47 majority. Of the 100 seats, 35 are being voted on this election, and 23 of those are held by Republicans. Seats that had been regarded as safely Republican, including in Alaska, Iowa, North Carolina, Kansas and Montana, are now in Democrat sights. Lindsey Graham, a close presidential ally, is now in a tied race in South Carolina. As they returned to their states to campaign some Republican senators, although not Mr Graham, have been notably cool in their comments about the

Read the rest
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AMAG Pharmaceuticals, Inc. – AMAG

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AMAG Pharmaceuticals, Inc. – AMAG

NEW YORK, Oct. 9, 2020 /PRNewswire/ — Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating AMAG Pharmaceuticals, Inc. (“AMAG” or the “Company”) (AMAG) relating to its acquisition by Covis Group S.à.r.l. Under the terms of the agreement, AMAG shareholders shall be entitled to receive $13.75 in cash for each share of AMAG common stock owned.

Monteverde & Associates PC Logo

The investigation focuses on whether AMAG and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process and  2) whether and by how much this proposed transaction undervalues the Company.

Click here for more information: https://www.monteverdelaw.com/case/american-renal-associates-holdings-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.  Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions.  Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.  Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019).  Also, in 2019 we recovered or secured six cash common

Read the rest
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on
their Investment in BioMarin Pharmaceuticals, Inc. of Class Action Lawsuit and
Upcoming Deadline – BMRN

NEW YORK, Oct.  08, 2020 (GLOBE  NEWSWIRE) -- Pomerantz  LLP announces that  a
class action lawsuit  has been  filed against  BioMarin Pharmaceuticals,  Inc.
 (“BioMarin” or the “Company”)  (NASDAQ: BMRN) and  certain of its  officers. 
The class  action, filed  in United  States District  Court for  the  Northern
District of California,  and docketed  under 20-cv-06719,  is on  behalf of  a
class consisting  of  all  persons  other than  Defendants  who  purchased  or
otherwise, acquired BioMarin securities between  February 28, 2020 and  August
18, 2020,  both  dates inclusive  (the  “Class Period”),  seeking  to  recover
damages caused by Defendants’ violations of the federal securities laws and to
pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange  Act
of 1934 (the “Exchange  Act”) and Rule  10b-5 promulgated thereunder,  against
the Company and certain of its top officials.

If you are a  shareholder who purchased BioMarin  securities during the  class
period, you have until November 24, 2020,  to ask the Court to appoint you  as
Lead Plaintiff for  the class.  A  copy of  the Complaint can  be obtained  at
www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at
newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.  7980.
Those who inquire by e-mail are  encouraged to include their mailing  address,
telephone number, and the number of shares purchased. 

         [Click here for information about joining the class action]

BioMarin is a biotechnology company that develops and commercializes therapies
for people  with  serious  and  life-threatening  rare  diseases  and  medical
conditions.  The   Company’s  product   candidates  include,   among   others,
valoctocogene roxaparvovec, an investigational adeno-associated virus  (“AAV”)
gene therapy, which is  in Phase 3 clinical  development for the treatment  of
patients with severe hemophilia A.

Based 
Read the rest